Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT05870540

ClinicalTrials.gov

Trial ID
T-ctgov-NCT05870540
Registry
ClinicalTrials.gov
NCT number
NCT05870540
Asset
BPL-003
Sponsor, as registered
Beckley Psytech Limited
Phase
PHASE2
Indication
Treatment Resistant Depression
Status
COMPLETED
Start date
2023-09-14
Primary completion
2025-03-28
Registered countries
Australia, Germany, Poland, Spain, United Kingdom, United States
Sites
42

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-15

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site. Supersedes the row verified 2026-08-31. Record last updated 2026-09-10; overall_status COMPLETED and primary_completion_date 2025-03-28 unchanged; the API does not expose what changed.

Company

Through BPL-003: Beckley Psytech and AtaiBeckley

Cited in

Issues quoting NCT05870540 in their own text.